JP2011529919A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011529919A5 JP2011529919A5 JP2011521362A JP2011521362A JP2011529919A5 JP 2011529919 A5 JP2011529919 A5 JP 2011529919A5 JP 2011521362 A JP2011521362 A JP 2011521362A JP 2011521362 A JP2011521362 A JP 2011521362A JP 2011529919 A5 JP2011529919 A5 JP 2011529919A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- iodine
- fluorine
- bromine
- radioactive isotope
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 230000002285 radioactive effect Effects 0.000 claims 22
- 229910052731 fluorine Inorganic materials 0.000 claims 20
- 239000011737 fluorine Substances 0.000 claims 20
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims 18
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 16
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 16
- 229910052794 bromium Inorganic materials 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical group II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 125000003118 aryl group Chemical group 0.000 claims 10
- 125000001072 heteroaryl group Chemical group 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 9
- 229910052789 astatine Inorganic materials 0.000 claims 8
- RYXHOMYVWAEKHL-UHFFFAOYSA-N astatine atom Chemical compound [At] RYXHOMYVWAEKHL-UHFFFAOYSA-N 0.000 claims 8
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 6
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 229910052740 iodine Inorganic materials 0.000 claims 6
- 239000011630 iodine Substances 0.000 claims 6
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 5
- 229910052799 carbon Inorganic materials 0.000 claims 5
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 239000000460 chlorine Substances 0.000 claims 5
- 238000010276 construction Methods 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 239000000203 mixture Substances 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 150000003536 tetrazoles Chemical class 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- DWOUTQIADYZYML-UHFFFAOYSA-N [Br].[At] Chemical compound [Br].[At] DWOUTQIADYZYML-UHFFFAOYSA-N 0.000 claims 1
- SYKNUAWMBRIEKB-UHFFFAOYSA-N [Cl].[Br] Chemical compound [Cl].[Br] SYKNUAWMBRIEKB-UHFFFAOYSA-N 0.000 claims 1
- 210000005013 brain tissue Anatomy 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000005084 renal tissue Anatomy 0.000 claims 1
- 230000002792 vascular Effects 0.000 claims 1
- 0 *c1ccc(C=NNc(cc2)ccc2C(NCCCCC(C(O)=O)NC(NC(CCC(O)=O)C(O)=O)=O)=O)cc1 Chemical compound *c1ccc(C=NNc(cc2)ccc2C(NCCCCC(C(O)=O)NC(NC(CCC(O)=O)C(O)=O)=O)=O)cc1 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8546208P | 2008-08-01 | 2008-08-01 | |
| US61/085,462 | 2008-08-01 | ||
| US11179108P | 2008-11-06 | 2008-11-06 | |
| US61/111,791 | 2008-11-06 | ||
| PCT/US2009/052456 WO2010014933A2 (en) | 2008-08-01 | 2009-07-31 | Psma-binding agents and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014152130A Division JP5806765B2 (ja) | 2008-08-01 | 2014-07-25 | Ｐｓｍａ結合剤及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011529919A JP2011529919A (ja) | 2011-12-15 |
| JP2011529919A5 true JP2011529919A5 (https=) | 2012-09-20 |
| JP5588441B2 JP5588441B2 (ja) | 2014-09-10 |
Family
ID=41610978
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011521362A Active JP5588441B2 (ja) | 2008-08-01 | 2009-07-31 | Ｐｓｍａ結合剤及びその使用 |
| JP2014152130A Active JP5806765B2 (ja) | 2008-08-01 | 2014-07-25 | Ｐｓｍａ結合剤及びその使用 |
| JP2015174731A Active JP6030724B2 (ja) | 2008-08-01 | 2015-09-04 | Ｐｓｍａ結合剤及びその使用 |
| JP2016206120A Active JP6524046B2 (ja) | 2008-08-01 | 2016-10-20 | Ｐｓｍａ結合剤及びその使用 |
| JP2018220353A Active JP7277113B2 (ja) | 2008-08-01 | 2018-11-26 | Ｐｓｍａ結合剤及びその使用 |
| JP2021012046A Active JP7219497B2 (ja) | 2008-08-01 | 2021-01-28 | Ｐｓｍａ結合剤及びその使用 |
Family Applications After (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014152130A Active JP5806765B2 (ja) | 2008-08-01 | 2014-07-25 | Ｐｓｍａ結合剤及びその使用 |
| JP2015174731A Active JP6030724B2 (ja) | 2008-08-01 | 2015-09-04 | Ｐｓｍａ結合剤及びその使用 |
| JP2016206120A Active JP6524046B2 (ja) | 2008-08-01 | 2016-10-20 | Ｐｓｍａ結合剤及びその使用 |
| JP2018220353A Active JP7277113B2 (ja) | 2008-08-01 | 2018-11-26 | Ｐｓｍａ結合剤及びその使用 |
| JP2021012046A Active JP7219497B2 (ja) | 2008-08-01 | 2021-01-28 | Ｐｓｍａ結合剤及びその使用 |
Country Status (25)
| Country | Link |
|---|---|
| US (7) | US8778305B2 (https=) |
| EP (3) | EP2318366B1 (https=) |
| JP (6) | JP5588441B2 (https=) |
| KR (1) | KR101664855B1 (https=) |
| CN (3) | CN102171187B (https=) |
| AU (1) | AU2009276423B2 (https=) |
| CA (2) | CA2732632C (https=) |
| CY (3) | CY1119367T1 (https=) |
| DK (2) | DK3222615T3 (https=) |
| ES (2) | ES2634894T3 (https=) |
| FI (1) | FIC20230033I1 (https=) |
| FR (1) | FR23C1044I2 (https=) |
| HK (1) | HK1247197A1 (https=) |
| HR (2) | HRP20220742T1 (https=) |
| HU (3) | HUE034027T2 (https=) |
| LT (3) | LT2318366T (https=) |
| LU (1) | LUC00323I2 (https=) |
| NL (1) | NL301250I2 (https=) |
| NO (1) | NO2024006I1 (https=) |
| PL (2) | PL2318366T3 (https=) |
| PT (2) | PT2318366T (https=) |
| RU (1) | RU2494096C2 (https=) |
| SI (2) | SI2318366T1 (https=) |
| SM (1) | SMT201700371T1 (https=) |
| WO (1) | WO2010014933A2 (https=) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4464384A3 (en) | 2007-08-17 | 2025-01-08 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
| WO2009070302A1 (en) * | 2007-11-30 | 2009-06-04 | The Johns Hopkins University | Prostate specific membrane antigen (psma) targeted nanoparticles for therapy of prostate cancer |
| USRE47609E1 (en) | 2007-12-28 | 2019-09-17 | Exini Diagnostics Ab | System for detecting bone cancer metastases |
| RU2494096C2 (ru) * | 2008-08-01 | 2013-09-27 | Дзе Джонс Хопкинс Юниверсити | Агенты, связывающиеся с psma, и их применение |
| AU2010249719A1 (en) | 2009-05-19 | 2012-05-31 | Aic Blab Company | Composite current collector and methods therefor |
| US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
| WO2013028664A1 (en) | 2011-08-22 | 2013-02-28 | Siemens Medical Solutions Usa, Inc. | Psma imaging agents |
| US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
| CN113149921B (zh) * | 2011-11-30 | 2024-11-29 | 约翰霍普金斯大学 | 前列腺特异性膜抗原(psma)的同源多价抑制剂和异源多价抑制剂以及其用途 |
| US20140065070A1 (en) * | 2012-08-28 | 2014-03-06 | Mcmaster University | Methods of preparing triazole-containing radioiodinated compounds |
| BR112015011118B1 (pt) * | 2012-11-15 | 2022-12-13 | Endocyte, Inc | Conjugado; composição farmacêutica; e uso de um conjugado |
| SI2970345T1 (sl) * | 2013-03-15 | 2019-11-29 | Cancer Targeted Tech Llc | 18F-označena PSMA-ciljana sredstva za pet slikanje |
| WO2015057692A1 (en) | 2013-10-14 | 2015-04-23 | The Johns Hopkins University | Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy |
| LT4095130T (lt) | 2013-10-18 | 2024-04-25 | Novartis Ag | Žymėti prostatos specifinio membranos antigeno (psma) inhibitoriai, jų naudojimas kaip vizualizavimo medžiagų ir farmacinių medžiagų prostatos vėžiui gydyti |
| JP6292568B2 (ja) * | 2013-11-06 | 2018-03-14 | 国立大学法人京都大学 | ウレア誘導体化合物、これを含有する放射性医薬 |
| BR112016010927A2 (pt) | 2013-11-14 | 2017-08-08 | Endocyte Inc | Conjugado de fórmula |
| US9713649B2 (en) | 2014-01-24 | 2017-07-25 | The Cleveland Clinic Foundation | PSMA-targeting imaging agents |
| US10556916B2 (en) * | 2014-04-01 | 2020-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography |
| EP3183236B1 (en) | 2014-08-24 | 2022-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
| EP2993171A1 (en) * | 2014-09-04 | 2016-03-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the production of 18F-labeled PSMA-specific PET-tracers |
| EP3209336B1 (en) * | 2014-10-20 | 2019-12-11 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| EP3011976A1 (en) * | 2014-10-20 | 2016-04-27 | Deutsches Krebsforschungszentrum | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents |
| US10736974B2 (en) | 2014-10-22 | 2020-08-11 | The Johns Hopkins University | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy |
| US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
| WO2016112382A2 (en) * | 2015-01-09 | 2016-07-14 | The Johns Hopkins University | Intranasal administration of glutamate carboxypeptidase (gcp-ii) inhibitors |
| US10869940B2 (en) | 2015-06-12 | 2020-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted photoacoustic compounds, formulations, and uses thereof |
| WO2017029399A1 (en) * | 2015-08-20 | 2017-02-23 | Universität Zu Köln | Pain tracking by pet-imaging (pain-trap) |
| AU2016333334B2 (en) | 2015-09-30 | 2019-07-25 | Deutsches Krebsforschungszentrum | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA) and their use as imaging agents for prostate cancer |
| WO2017070482A2 (en) * | 2015-10-22 | 2017-04-27 | The Johns Hopkins University | Psma targeted radiohalogenated ureas for cancer radiotherapy |
| KR101639599B1 (ko) | 2015-11-09 | 2016-07-14 | 서울대학교산학협력단 | 펩타이드 싸이오우레아 유도체, 이를 포함하는 방사성 동위원소 표지 화합물 및 이를 유효 성분으로 함유하는 전립선암 치료 또는 진단용 약학적 조성물 |
| WO2017117687A1 (en) | 2016-01-10 | 2017-07-13 | British Columbia Cancer Agency Branch | 18/19f-labelled compounds which target the prostate specific membrane antigen |
| HUE069964T2 (hu) * | 2016-06-10 | 2025-04-28 | Univ Johns Hopkins | Javított eljárás a radiojelölt prosztata-specifikus membrán antigén (prostate-specific membrane antigen, psma) gátló [18f]DCFPyL elõállítására |
| US10806806B2 (en) | 2016-06-23 | 2020-10-20 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
| CN109843339B (zh) * | 2016-06-23 | 2023-07-07 | 康奈尔大学 | 影响肿瘤杀伤的双重靶向构建体 |
| CN113035327B (zh) | 2016-10-27 | 2025-02-07 | 普罗热尼奇制药公司 | 用于医学图像分析的网络、决策支持系统和相关图形用户界面(gui)应用 |
| WO2018090974A1 (zh) * | 2016-11-17 | 2018-05-24 | 思路迪（北京）医药科技有限公司 | 一种具有抗癌作用的化合物及其制备方法和应用 |
| DE102016122273B4 (de) * | 2016-11-18 | 2018-06-21 | Abx Advanced Biochemical Compounds Gmbh | Präkursoren für die Radiofluorierung |
| IL315062A (en) | 2017-04-05 | 2024-10-01 | Univ Cornell | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
| EP3607319A1 (en) * | 2017-04-07 | 2020-02-12 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods |
| WO2018204477A1 (en) | 2017-05-02 | 2018-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
| EP3643707B1 (en) | 2017-06-19 | 2022-02-23 | Futurechem Co., Ltd. | 18f-labelled compound for prostate cancer diagnosis, and use thereof |
| WO2018236115A1 (ko) | 2017-06-19 | 2018-12-27 | (주)퓨쳐켐 | 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도 |
| EA202090776A1 (ru) | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | Визуализирующие и радиотерапевтические агенты, нацеленные на фибробласт-активирующий белок-альфа (fapalpha) |
| BR112020011727A2 (pt) * | 2017-12-11 | 2020-11-17 | Technische Universität München | ligantes de psma para imageamento e endorradioterapia |
| JP7448476B2 (ja) | 2018-01-08 | 2024-03-12 | プロジェニクス ファーマシューティカルズ， インコーポレイテッド | 高速ニューラルネットワークベースの画像セグメント化および放射性医薬品摂取判定のためのシステムおよび方法 |
| US10973486B2 (en) | 2018-01-08 | 2021-04-13 | Progenics Pharmaceuticals, Inc. | Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination |
| US12602772B2 (en) | 2018-01-08 | 2026-04-14 | Progenics Pharmaceuticals, Inc. | Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination |
| KR20250126870A (ko) | 2018-02-06 | 2025-08-25 | 더 존스 홉킨스 유니버시티 | 암 방사선 치료를 위한 psma 표적 방사성 할로겐화 우레아-폴리아미노카복실레이트 |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| US12208102B2 (en) | 2018-04-17 | 2025-01-28 | Endocyte, Inc. | Methods of treating cancer |
| CN109160896B (zh) * | 2018-05-16 | 2021-06-25 | 上海如絮生物科技有限公司 | 一种亲水性吡啶类化合物中间体及其制备方法 |
| CN109160899B (zh) * | 2018-05-16 | 2021-06-04 | 上海如絮生物科技有限公司 | 一种亲水性吡啶类化合物、中间体、其制备方法及应用 |
| CN109160898B (zh) * | 2018-05-16 | 2021-06-04 | 上海如絮生物科技有限公司 | 一种亲水性吡啶类化合物中间体及其制备方法 |
| WO2020028323A1 (en) * | 2018-07-30 | 2020-02-06 | The Johns Hopkins Universtiy | Competitive prostate-specific membrane antigen (psma) binding agents for the reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy |
| CN113164450A (zh) | 2018-10-11 | 2021-07-23 | 普罗热尼奇制药公司 | 用于治疗转移性前列腺癌的组合治疗 |
| RU2697519C1 (ru) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Средство пептидной природы, включающее псма-связывающий лиганд на основе производного мочевины, способ его получения и применение для получения конъюгата с лекарственным и диагностическим агентом |
| KR102403970B1 (ko) | 2018-12-27 | 2022-05-31 | (주)퓨쳐켐 | 카르복시산이 도입된 psma-표적 화합물 및 그의 용도 |
| JP7568628B2 (ja) | 2019-01-07 | 2024-10-16 | エクシーニ ディアグノスティクス アーべー | プラットホーム非依存の全身画像セグメント化のためのシステムおよび方法 |
| PL239934B1 (pl) | 2019-04-12 | 2022-01-31 | Narodowe Centrum Badan Jadrowych Osrodek Radioizotopow Polatom | Pochodne inhibitorów PSMA do znakowania ⁹⁹ᵐTc poprzez HYNIC, zestaw radiofarmaceutyczny, preparat radiofarmaceutyczny oraz ich zastosowanie w diagnostyce raka prostaty |
| WO2020210909A1 (en) | 2019-04-17 | 2020-10-22 | Provincial Health Services Authority | Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer |
| EP4564288A3 (en) | 2019-04-24 | 2025-09-17 | Progenics Pharmaceuticals, Inc. | Systems and methods for automated and interactive analysis of bone scan images for detection of metastases |
| JP7539921B2 (ja) | 2019-04-24 | 2024-08-26 | プロジェニクス ファーマシューティカルズ， インコーポレイテッド | 核医学画像における強度ウィンドウ処理の双方向調節のためのシステムおよび方法 |
| CN114096264B (zh) | 2019-05-20 | 2025-03-14 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| CN114401947B (zh) | 2019-06-21 | 2024-11-29 | 省卫生服务机构 | 靶向前列腺特异性膜抗原的放射性标记化合物 |
| RU2713151C1 (ru) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Конъюгат флуоресцентного красителя с веществом пептидной природы, включающим псма-связывающий лиганд на основе производного мочевины для визуализации клеток, экспрессирующих псма, способ его получения и применения |
| WO2021041896A1 (en) * | 2019-08-30 | 2021-03-04 | Memorial Sloan Kettering Cancer Center | Novel theranostic agents for psma positive cancers |
| US11900597B2 (en) | 2019-09-27 | 2024-02-13 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| US11564621B2 (en) | 2019-09-27 | 2023-01-31 | Progenies Pharmacenticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| US12417533B2 (en) | 2019-09-27 | 2025-09-16 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
| US11544407B1 (en) | 2019-09-27 | 2023-01-03 | Progenics Pharmaceuticals, Inc. | Systems and methods for secure cloud-based medical image upload and processing |
| KR102269315B1 (ko) | 2019-10-24 | 2021-06-24 | 서울대학교산학협력단 | 전립선 암의 영상 또는 치료를 위한 동위원소 표지 화합물 |
| US11321844B2 (en) | 2020-04-23 | 2022-05-03 | Exini Diagnostics Ab | Systems and methods for deep-learning-based segmentation of composite images |
| US11386988B2 (en) | 2020-04-23 | 2022-07-12 | Exini Diagnostics Ab | Systems and methods for deep-learning-based segmentation of composite images |
| CN111548305B (zh) * | 2020-05-12 | 2021-08-31 | 北京师范大学 | 一种可用于靶向psma的喹啉类化合物及其制备方法 |
| US11721428B2 (en) | 2020-07-06 | 2023-08-08 | Exini Diagnostics Ab | Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions |
| WO2022008374A1 (en) | 2020-07-06 | 2022-01-13 | Exini Diagnostics Ab | Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions |
| EP4244216A1 (en) | 2020-11-12 | 2023-09-20 | ABX Advanced Biochemical Compounds GmbH | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
| CN114685599A (zh) * | 2020-12-30 | 2022-07-01 | 南京江原安迪科正电子研究发展有限公司 | 一种psma靶向抑制剂及放射性核素标记的psma靶向抑制剂、制备方法和用途 |
| CA3227534A1 (en) | 2021-07-30 | 2023-02-02 | Yoshifumi Shirakami | Radiolabeled compound and use thereof |
| US12597127B2 (en) | 2021-10-08 | 2026-04-07 | Exini Diagnostics Ab | Systems and methods for automated identification and classification of lesions in local lymph and distant metastases |
| CA3237590A1 (en) | 2021-11-09 | 2023-05-08 | James Basilion | Psma targeted conjugate compounds and uses thereof |
| AU2023282844A1 (en) | 2022-06-08 | 2024-11-28 | Exini Diagnostics Ab | Systems and methods for assessing disease burden and progression |
| AU2024208501A1 (en) | 2023-01-10 | 2025-07-24 | Sun Pharma Advanced Research Company Limited | Ligand-drug conjugates |
| US20240285248A1 (en) | 2023-02-13 | 2024-08-29 | Progenics Pharmaceuticals, Inc. | Systems and methods for predicting biochemical progression free survival in prostate cancer patients |
| CN116217505B (zh) * | 2023-03-17 | 2024-10-01 | 南京医科大学 | 用于诊断或治疗表达前列腺特异性膜抗原癌症的新型标记靶向剂 |
| WO2024211651A1 (en) | 2023-04-07 | 2024-10-10 | Progenics Pharmaceuticals, Inc. | Systems and methods for facilitating lesion inspection and analysis |
| WO2025072177A1 (en) | 2023-09-25 | 2025-04-03 | Progenics Pharmaceuticals, Inc. | Systems and methods for automated cancer staging and risk prediction |
| WO2025090594A1 (en) * | 2023-10-25 | 2025-05-01 | The Johns Hopkins University | Deep transfer learning for fully automated tumor quantification and prognosis of cancer on pet/ct |
| DE102023133281B8 (de) * | 2023-11-28 | 2025-07-24 | Abx Advanced Biochemical Compounds - Biomedizinische Forschungsreagenzien Gmbh | Radiotracer und Präkursoren für diese Radiotracer sowie Verwendung dieser Radiotracer als Diagnostika und Therapeutika |
| CN117670883B (zh) * | 2024-01-31 | 2024-05-07 | 中国医学科学院北京协和医院 | 一种鉴别高低级别膀胱癌的方法、设备和系统 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2233269C2 (ru) * | 1998-11-02 | 2004-07-27 | Авентис Фарма Лимитед | Замещенные анилиды, фармацевтическая композиция и способ лечения |
| JP3750494B2 (ja) | 1999-08-31 | 2006-03-01 | 松下電器産業株式会社 | 半導体装置 |
| WO2006093991A1 (en) * | 2005-03-02 | 2006-09-08 | The Cleveland Clinic Foundation | Compounds which bind psma and uses thereof |
| ES2847275T3 (es) | 2006-11-08 | 2021-08-02 | Molecular Insight Pharm Inc | Heterodímeros de ácido glutámico |
| EP2136788B1 (en) * | 2007-03-30 | 2011-10-26 | Bind Biosciences, Inc. | Cancer cell targeting using nanoparticles |
| CA2926573C (en) * | 2007-06-26 | 2018-08-28 | The Johns Hopkins University | Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents |
| RU2494096C2 (ru) * | 2008-08-01 | 2013-09-27 | Дзе Джонс Хопкинс Юниверсити | Агенты, связывающиеся с psma, и их применение |
| GB0905438D0 (en) | 2009-03-30 | 2009-05-13 | Ge Healthcare Ltd | Radiolabelling reagents and methods |
| HUE069964T2 (hu) * | 2016-06-10 | 2025-04-28 | Univ Johns Hopkins | Javított eljárás a radiojelölt prosztata-specifikus membrán antigén (prostate-specific membrane antigen, psma) gátló [18f]DCFPyL elõállítására |
-
2009
- 2009-07-31 RU RU2011107752/04A patent/RU2494096C2/ru active
- 2009-07-31 WO PCT/US2009/052456 patent/WO2010014933A2/en not_active Ceased
- 2009-07-31 JP JP2011521362A patent/JP5588441B2/ja active Active
- 2009-07-31 PL PL09803670T patent/PL2318366T3/pl unknown
- 2009-07-31 CA CA2732632A patent/CA2732632C/en active Active
- 2009-07-31 HU HUE09803670A patent/HUE034027T2/en unknown
- 2009-07-31 ES ES09803670.0T patent/ES2634894T3/es active Active
- 2009-07-31 CN CN200980139135.3A patent/CN102171187B/zh active Active
- 2009-07-31 HU HUE17167057A patent/HUE059436T2/hu unknown
- 2009-07-31 CA CA2987744A patent/CA2987744C/en active Active
- 2009-07-31 US US13/057,044 patent/US8778305B2/en active Active
- 2009-07-31 ES ES17167057T patent/ES2914593T3/es active Active
- 2009-07-31 EP EP09803670.0A patent/EP2318366B1/en active Active
- 2009-07-31 CN CN201710536671.3A patent/CN107382846B/zh active Active
- 2009-07-31 DK DK17167057.3T patent/DK3222615T3/da active
- 2009-07-31 HR HRP20220742TT patent/HRP20220742T1/hr unknown
- 2009-07-31 HR HRP20171133TT patent/HRP20171133T1/hr unknown
- 2009-07-31 PT PT98036700T patent/PT2318366T/pt unknown
- 2009-07-31 EP EP22163541.0A patent/EP4089074A1/en active Pending
- 2009-07-31 SI SI200931704T patent/SI2318366T1/sl unknown
- 2009-07-31 EP EP17167057.3A patent/EP3222615B1/en active Active
- 2009-07-31 PL PL17167057.3T patent/PL3222615T3/pl unknown
- 2009-07-31 PT PT171670573T patent/PT3222615T/pt unknown
- 2009-07-31 SM SM20170371T patent/SMT201700371T1/it unknown
- 2009-07-31 SI SI200932167T patent/SI3222615T1/sl unknown
- 2009-07-31 DK DK09803670.0T patent/DK2318366T3/en active
- 2009-07-31 KR KR1020117004960A patent/KR101664855B1/ko active Active
- 2009-07-31 LT LTEP09803670.0T patent/LT2318366T/lt unknown
- 2009-07-31 CN CN202110689899.2A patent/CN113563262A/zh active Pending
- 2009-07-31 LT LTEP17167057.3T patent/LT3222615T/lt unknown
- 2009-07-31 AU AU2009276423A patent/AU2009276423B2/en active Active
-
2012
- 2012-02-27 HK HK18106684.8A patent/HK1247197A1/zh unknown
-
2014
- 2014-03-14 US US14/211,683 patent/US9226981B2/en active Active
- 2014-07-25 JP JP2014152130A patent/JP5806765B2/ja active Active
-
2015
- 2015-09-04 JP JP2015174731A patent/JP6030724B2/ja active Active
-
2016
- 2016-01-04 US US14/987,032 patent/US9861713B2/en active Active
- 2016-10-20 JP JP2016206120A patent/JP6524046B2/ja active Active
-
2017
- 2017-07-31 CY CY20171100825T patent/CY1119367T1/el unknown
-
2018
- 2018-01-08 US US15/864,236 patent/US10500292B2/en active Active
- 2018-11-26 JP JP2018220353A patent/JP7277113B2/ja active Active
-
2019
- 2019-11-05 US US16/674,089 patent/US20200282083A1/en not_active Abandoned
-
2021
- 2021-01-28 JP JP2021012046A patent/JP7219497B2/ja active Active
- 2021-04-22 US US17/237,850 patent/US12070513B2/en active Active
-
2022
- 2022-06-09 CY CY20221100403T patent/CY1125468T1/el unknown
-
2023
- 2023-11-02 FI FIC20230033C patent/FIC20230033I1/fi unknown
- 2023-11-03 CY CY2023024C patent/CY2023024I2/el unknown
- 2023-11-06 FR FR23C1044C patent/FR23C1044I2/fr active Active
- 2023-11-14 HU HUS2300039C patent/HUS2300039I1/hu unknown
- 2023-11-14 LT LTPA2023534C patent/LTC2318366I2/lt unknown
- 2023-11-15 NL NL301250C patent/NL301250I2/nl unknown
- 2023-12-01 LU LU00323C patent/LUC00323I2/fr unknown
-
2024
- 2024-02-01 NO NO2024006C patent/NO2024006I1/no unknown
- 2024-07-15 US US18/772,628 patent/US20250177578A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011529919A5 (https=) | ||
| JP7304588B2 (ja) | Ｐｓｍａを標的としたイメージング及び放射線治療のための金属／放射性金属標識ｐｓｍａ阻害剤 | |
| RU2011107752A (ru) | Агенты, связывающиеся с psma, и их применение | |
| JP2018058847A5 (https=) | ||
| AU2008237932C1 (en) | 18 F-labelled folates | |
| RU2008150377A (ru) | Новое соединение, обладающее сродством к амилоиду | |
| JP2019505585A5 (https=) | ||
| JP2012520271A5 (https=) | ||
| RU2008147002A (ru) | Новые соединения, обладающие сродством к амилоиду | |
| JP2019527740A5 (https=) | ||
| JP2013504590A5 (https=) | ||
| Lin et al. | Preparation and biodistribution of a 99mTc tricarbonyl complex with deoxyglucose dithiocarbamate as a tumor imaging agent for SPECT | |
| CN102977174A (zh) | 99mTc(CO)3核标记大环多胺三唑环类葡萄糖基配合物及制备方法和应用 | |
| Wang et al. | Synthesis, radiolabeling and biodistribution studies of [99m Tc (CO) 3 (MN-TZ-BPA)]+ in tumor-bearing mice | |
| JP2015500873A5 (https=) | ||
| Class et al. | Patent application title: METAL/RADIOMETAL-LABELED PSMA INHIBITORS FOR PSMA-TARGETED IMAGING AND RADIOTHERAPY | |
| KR102190674B1 (ko) | 리간드 화합물이 결합된 사카린 나트륨, 그 유도체 및 그 제조방법 | |
| US20260007781A1 (en) | Prostate specific membrane antigen (psma) ligands and uses thereof | |
| EP3747874A1 (en) | Sodium saccharin having conjugated ligand, derivatives thereof and process for the preparation thereof | |
| Qiu et al. | Pharmacokinetic and imaging evaluation of 99m Tc-HBIDP as a potential bone imaging agent | |
| Скуридин et al. | SECTION 1-Methods and facilities of diagnostic and treatment 65 | |
| RU2020120946A (ru) | Комплекс, содержащий нацеливающееся на psma соединение, связанное с радионуклидом свинца или тория |